Apr 15, 2025
Salt-tolerant endonucleases, the benefits for viral vector manufacturing and a comparison of two marketed enzymes
Cell & Gene Therapy Insights 2025; 11(3), 307–319 · DOI: 10.18609/cgti.2025.035Published: 26 March...
read more
Mar 25, 2025
c-LEcta Announces Launch of GMP Grade DENARASE® High Salt
Leipzig, Germany, 25th March 2025 – c-LEcta, a leading international supplier of enzymes for the...
read more
Sep 11, 2024
Highly efficient DNA removal in Viral Vector Manufacturing
In this presentation we will show you how we used our proprietary engineering platform ENESYZ® for...
read more
Jul 30, 2024
Upcoming Webinar: Salt-tolerant endonucleases and the benefits for viral vector manufacturing, and a comparison of two marketed enzymes
Tuesday 27th August 202408:00 PDT / 11:00 EDT / 16:00 BST / 17:00 CEST Live30 webinars are...
read more
Mar 5, 2024
c-LEcta launches DENARASE® High Salt for enhanced process flexibility in Viral Vector Manufacturing
c-LEcta, a leading international supplier of enzymes for the biopharmaceutical industry announces...
read more
Sep 28, 2023
How to compare the technical performance of 𝙎𝙚𝙧𝙧𝙖𝙩𝙞𝙖 𝙢𝙖𝙧𝙘𝙚𝙨𝙘𝙚𝙣𝙨 endonucleases such as DENARASE & Benzonase?
Endonucleases are widely used in the manufacturing of viral vectors for cell and gene therapies....
read more
Sep 13, 2023
c-LEcta increases market presence in the USA
c-LEcta establishes a US warehouse for R&D-grade DENARASE® portfolio and partners with local...
read more
Jun 26, 2023
c-LEcta @ Bioprocessing Summit & BPI Boston
In August and September c-LEcta is presenting their DENARASE® portfolio: DENARASE® for research and...
read more
May 4, 2023
Accelerate the Manufacturing of Gene and Cell Therapies with GMP Enzymes from c-LEcta
During BPI US West in San Diego, our Head of Marketing Raphael Gübeli talked about recent trends...
read more
Apr 19, 2023
US FDA DMF Support for DENARASE® GMP-grade
c-LEcta successfully filed a Drug Master File (Type II) with the US FDA in 2021. We spoke with Dr....
read more